Literature DB >> 20139913

A preliminary trial to determine whether prevention of dark adaptation affects the course of early diabetic retinopathy.

G B Arden1, M K Gündüz, A Kurtenbach, M Völker, E Zrenner, S B Gündüz, U Kamis, B T Oztürk, S Okudan.   

Abstract

UNLABELLED: This study was designed to determine whether a new form of treatment of diabetic retinopathy (DR) was acceptable to patients and whether reduction in the maximal activity of rods in diabetes could affect the progress of DR.
METHODS: In 12 patients, trans-lid retinal illumination of one eye was employed during sleep to prevent the depolarisation of rods and thus reduce their metabolic activity. TECHNIQUES: A headband was used to place a source of chemical light over one eye, with its fellow as a control. MEASUREMENTS: Colour contrast thresholds were measured before and after a period of treatment in treated eyes, and the changes were compared to those in untreated fellow eyes, and areas of 'dark retinal anomalies' (microaneurysms, dot haemorrhages) were measured at the same time points.
RESULTS: Patients found this intervention to be acceptable, and no adverse effects were noted. In the majority of cases, and for each outcome measure, the treated eyes improved relative to their fellows. The intervention significantly reduced the tritan thresholds in treated eyes relative to their fellows (P=0.03), and the area of dark retinal anomalies decreased in treated eyes and increased in untreated eyes, with a similar probability.
CONCLUSIONS: The study showed that this intervention is safe. Although the study was not powered to study efficacy, the results are promising and consistent with other reports that indicate the retina in DR is suffering from hypoxia; however, further trials should be undertaken.

Entities:  

Mesh:

Year:  2010        PMID: 20139913     DOI: 10.1038/eye.2009.328

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  24 in total

Review 1.  The pathogenesis of early retinal changes of diabetic retinopathy.

Authors:  G B Arden; S Sivaprasad
Journal:  Doc Ophthalmol       Date:  2012-02       Impact factor: 2.379

2.  Safety and acceptability of an organic light-emitting diode sleep mask as a potential therapy for retinal disease.

Authors:  J N Sahni; G Czanner; T Gutu; S A Taylor; K M Bennett; S M Wuerger; I Grierson; C Murray-Dunning; M N Holland; S P Harding
Journal:  Eye (Lond)       Date:  2016-12-16       Impact factor: 3.775

Review 3.  Mechanistic Insights into Pathological Changes in the Diabetic Retina: Implications for Targeting Diabetic Retinopathy.

Authors:  Sayon Roy; Timothy S Kern; Brian Song; Caren Stuebe
Journal:  Am J Pathol       Date:  2016-11-12       Impact factor: 4.307

Review 4.  Retinal oxygen: from animals to humans.

Authors:  Robert A Linsenmeier; Hao F Zhang
Journal:  Prog Retin Eye Res       Date:  2017-01-18       Impact factor: 21.198

Review 5.  Do photoreceptor cells cause the development of retinal vascular disease?

Authors:  Timothy S Kern
Journal:  Vision Res       Date:  2017-05-08       Impact factor: 1.886

Review 6.  Hypoxia and Dark Adaptation in Diabetic Retinopathy: Interactions, Consequences, and Therapy.

Authors:  David J Ramsey; G B Arden
Journal:  Curr Diab Rep       Date:  2015-12       Impact factor: 4.810

Review 7.  Spare the rods and spoil the retina: revisited.

Authors:  S Sivaprasad; G Arden
Journal:  Eye (Lond)       Date:  2015-12-11       Impact factor: 3.775

8.  Photoreceptor responses to light in the pathogenesis of diabetic retinopathy.

Authors:  Shahriyar P Majidi; Rithwick Rajagopal
Journal:  Vis Neurosci       Date:  2020-09-14       Impact factor: 3.241

Review 9.  Interrelationships between the Retinal Neuroglia and Vasculature in Diabetes.

Authors:  Timothy S Kern
Journal:  Diabetes Metab J       Date:  2014-06       Impact factor: 5.376

10.  Photoreceptor cells are major contributors to diabetes-induced oxidative stress and local inflammation in the retina.

Authors:  Yunpeng Du; Alexander Veenstra; Krzysztof Palczewski; Timothy S Kern
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-25       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.